Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$21.79 +2.9%	$17.32	$9.57 ▼ $27.34	$3.01B	0.94	1.96 million shs	2.08 million shs
BVNRY Bavarian Nordic	$12.16 -1.7%	$10.63	$6.60 ▼ $13.51	$2.88B	1.36	7,783 shs	1,617 shs
OXBDF Oxford BioMedica	$7.35	$5.41	$3.15 ▼ $7.35	$778.81M	1.08	963 shs	N/A
XENE Xenon Pharmaceuticals	$38.87 +0.6%	$33.42	$26.74 ▼ $46.00	$3.00B	1.16	890,313 shs	407,733 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+2.27%	+6.65%	+34.56%	+36.12%	-14.25%
BVNRY Bavarian Nordic	+0.90%	+1.10%	+1.60%	+42.29%	-9.68%
OXBDF Oxford BioMedica	0.00%	+9.41%	+42.17%	+87.18%	+59.78%
XENE Xenon Pharmaceuticals	+1.34%	+3.45%	+27.56%	+35.66%	-5.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.7587 of 5 stars	3.5	1.0	0.0	3.4	3.0	2.5	0.0
BVNRY Bavarian Nordic	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OXBDF Oxford BioMedica	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	2.0936 of 5 stars	3.5	1.0	0.0	0.0	2.8	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	3.00	Buy	$43.14	97.99% Upside
BVNRY Bavarian Nordic	0.00	N/A	N/A	N/A
OXBDF Oxford BioMedica	0.00	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	3.00	Buy	$53.20	36.87% Upside

Current Analyst Ratings Breakdown

Latest OXBDF, XENE, ARWR, and BVNRY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	XENE Xenon Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00
8/12/2025	XENE Xenon Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$57.00 ➝ $55.00
8/12/2025	XENE Xenon Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$42.00 ➝ $43.00
8/11/2025	ARWR Arrowhead Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/11/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
8/8/2025	ARWR Arrowhead Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$40.00 ➝ $38.00
7/28/2025	ARWR Arrowhead Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$572.98M	5.26	N/A	N/A	$3.76 per share	5.80
BVNRY Bavarian Nordic	$829.12M	3.47	$1.00 per share	12.10	$6.99 per share	1.74
OXBDF Oxford BioMedica	$111.34M	6.99	N/A	N/A	$1.01 per share	7.28
XENE Xenon Pharmaceuticals	$9.43M	317.84	N/A	N/A	$8.22 per share	4.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.28	N/A	N/A	N/A	N/A	-40.91%	-11.62%	N/A
BVNRY Bavarian Nordic	$143.26M	$0.87	13.98	11.58	N/A	21.95%	12.75%	10.23%	8/28/2025 (Estimated)
OXBDF Oxford BioMedica	-$195.90M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	-$234.33M	-$3.55	N/A	N/A	N/A	N/A	-38.50%	-36.47%	11/11/2025 (Estimated)

Latest OXBDF, XENE, ARWR, and BVNRY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/22/2025	Q2 2025	BVNRY Bavarian Nordic	N/A	$0.23	N/A	$0.23	N/A	$251.14 million
8/11/2025	Q2 2025	XENE Xenon Pharmaceuticals	-$1.03	-$1.07	-$0.04	-$1.07	N/A	N/A
8/7/2025	Q3 2025	ARWR Arrowhead Pharmaceuticals	-$0.94	-$1.26	-$0.32	-$1.26	$29.01 million	$27.77 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BVNRY Bavarian Nordic	N/A	N/A	N/A	N/A	N/A
OXBDF Oxford BioMedica	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.39	4.87	4.87
BVNRY Bavarian Nordic	N/A	2.81	1.44
OXBDF Oxford BioMedica	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	15.14	15.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
BVNRY Bavarian Nordic	N/A
OXBDF Oxford BioMedica	N/A
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
BVNRY Bavarian Nordic	N/A
OXBDF Oxford BioMedica	N/A
XENE Xenon Pharmaceuticals	4.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.26 million	132.31 million	Optionable
BVNRY Bavarian Nordic	1,611	236.57 million	N/A	Not Optionable
OXBDF Oxford BioMedica	891	105.96 million	N/A	Not Optionable
XENE Xenon Pharmaceuticals	210	77.11 million	73.97 million	Optionable

OXBDF, XENE, ARWR, and BVNRY Headlines

Recent News About These Companies

Russell Investments Group Ltd. Has $2.53 Million Stock Position in Xenon Pharmaceuticals Inc. $XENE

August 27 at 3:39 AM | marketbeat.com

Xenon Pharmaceuticals Inc. $XENE Shares Sold by T. Rowe Price Investment Management Inc.

August 26 at 4:49 AM | marketbeat.com

EntryPoint Capital LLC Makes New $298,000 Investment in Xenon Pharmaceuticals Inc. $XENE

August 25 at 5:07 AM | marketbeat.com

Did Higher-Than-Expected Losses Just Shift Xenon Pharmaceuticals' (XENE) Investment Narrative?

August 24 at 10:40 AM | finance.yahoo.com

Wellington Management Group LLP Has $127.13 Million Position in Xenon Pharmaceuticals Inc. $XENE

August 24 at 5:14 AM | marketbeat.com

Xenon Pharmaceuticals Inc. $XENE Shares Sold by Atika Capital Management LLC

August 23, 2025 | marketbeat.com

Candriam S.C.A. Lowers Holdings in Xenon Pharmaceuticals Inc. $XENE

August 23, 2025 | marketbeat.com

Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)

August 23, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. $XENE Shares Sold by Algert Global LLC

August 22, 2025 | marketbeat.com

An Intrinsic Calculation For Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Suggests It's 44% Undervalued

August 21, 2025 | finance.yahoo.com

Xenon Pharmaceuticals Inc. $XENE Shares Acquired by Aberdeen Group plc

August 21, 2025 | marketbeat.com

Lord Abbett & CO. LLC Sells 106,990 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

August 19, 2025 | marketbeat.com

What is Chardan Capital's Forecast for XENE FY2025 Earnings?

August 19, 2025 | marketbeat.com

FY2025 Earnings Estimate for XENE Issued By Chardan Capital

August 18, 2025 | americanbankingnews.com

XENE FY2025 EPS Estimate Decreased by Cantor Fitzgerald

August 16, 2025 | marketbeat.com

HC Wainwright Analysts Decrease Earnings Estimates for XENE

August 16, 2025 | marketbeat.com

Q3 EPS Estimate for Xenon Pharmaceuticals Lifted by Analyst

August 16, 2025 | marketbeat.com

William Blair Has Negative Estimate for XENE Q3 Earnings

August 16, 2025 | marketbeat.com

Q3 EPS Estimate for Xenon Pharmaceuticals Cut by Analyst

August 16, 2025 | americanbankingnews.com

Leerink Partnrs Issues Positive Outlook for XENE Earnings

August 16, 2025 | americanbankingnews.com

William Blair Has Pessimistic Outlook of XENE Q3 Earnings

August 16, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OXBDF, XENE, ARWR, and BVNRY Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$21.79 +0.61 (+2.88%)

Closing price 04:00 PM Eastern

Extended Trading

$21.36 -0.43 (-1.95%)

As of 05:42 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Bavarian Nordic OTCMKTS:BVNRY

$12.16 -0.21 (-1.66%)

As of 01:48 PM Eastern

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Oxford BioMedica OTCMKTS:OXBDF

$7.35 0.00 (0.00%)

As of 08/26/2025

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

Xenon Pharmaceuticals NASDAQ:XENE

$38.87 +0.22 (+0.57%)

Closing price 04:00 PM Eastern

Extended Trading

$38.86 0.00 (-0.01%)

As of 05:56 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time